TB Alliance Appoints First Chief Administrative Officer

Healthcare Executive Colleen Pero to Guide Growth of World's
Leading TB Drug Development Organization
NEW YORK--(Business Wire)--
The Global Alliance for TB Drug Development (TB Alliance), a
not-for-profit product development partnership accelerating the
discovery and development of new drugs to fight tuberculosis (TB),
today announced the appointment of Colleen Pero as the organization's
first Chief Administrative Officer. Ms. Pero will lead the expansion
of the TB Alliance's staff and internal operations as it advances the
largest and fastest-growing new TB drug pipeline in history.

Ms. Pero was most recently Senior Vice President of Corporate
Administration for Endo Pharmaceuticals. She brings to the TB Alliance
senior leadership and strategic planning expertise from over fifteen
years of healthcare sector experience in rapid growth organizations,
both for-profit and not-for-profit.

"With numerous drugs in or approaching clinical trials, a maturing
discovery portfolio, and several new strategic partnerships, the TB
Alliance is poised to escalate its research and development
activities, and expand its advocacy and policy work to ensure new
treatments are adopted and available." said Dr. Jerome Premmereur,
Chief Executive Officer and President of the TB Alliance. "Colleen
brings strong leadership to the TB Alliance and experience to build
and sustain the capabilities we need to achieve our urgent mission."

Ms. Pero has led many operational areas including strategic
business planning, information technology, human resources,
communications, organizational development, public affairs, and
facilities planning. She has focused much of her career on the
development of fast-growing organizations and operational integration
during company expansion.

"Joining the TB Alliance at this pivotal stage in its growth is
very exciting," Pero said. "We have truly compelling goals and are
building all the ingredients for success: a strong portfolio of
promising drugs; a highly talented staff with a passionate commitment
to patients; and an exceptionally capable operation."

Every year, more than 1.5 million people worldwide die from TB. It
is estimated that the bacillus that causes TB infects one-third of the
world's population and the threat of drug-resistance is growing at an
alarming rate. New, faster-acting, simpler drug regimens are critical
to defeating this ancient disease.

About the Global Alliance for TB Drug Development

The TB Alliance is a not-for-profit, product development
partnership accelerating the discovery and development of new TB drugs
that will shorten treatment, be effective against susceptible and
resistant strains, be compatible with antiretroviral therapies for
those HIV-TB patients currently on such therapies, and improve
treatment of latent infection.

Working with public and private partners worldwide, the TB
Alliance is leading the development of the most comprehensive
portfolio of TB drug candidates in history, and is committed to
ensuring that approved new regimens are affordable, adopted and
available to those who need them.

The TB Alliance operates with funding from the Bill & Melinda
Gates Foundation, Irish Aid, the Netherlands Ministry of Foreign
Affairs (DGIS), the United Kingdom Department for International
Development (DFID), and the United States Agency for International
Development (USAID) and in-kind support from the National Institute
for Allergy and Infectious Diseases (NIAID). For more information on
TB drug development and the TB Alliance, please visit
www.tballiance.org.

Global Alliance for TB Drug Development
William Wells, +1-212-227-7540 x228
william.wells@tballiance.org

Copyright Business Wire 2008